- Home
- SLS
as 02-21-2025 4:00pm EST
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
| Founded: | 2012 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 100.6M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 4.0M |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.64 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.77 - $1.84 | Next Earning Date: | 03-27-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest SELLAS Life Sciences Group Inc. News
SLS Breaking Stock News: Dive into SLS Ticker-Specific Updates for Smart Investing
Clinical Trials Arena
a day ago
Sellas reports Phase IIa trial data of SLS009 for DLBCL treatment
GlobeNewswire
2 days ago
SELLAS Announces Positive Data from Phase 2a Trial of SLS009 in Combination with Zanubrutinib in DLBCL
GlobeNewswire
25 days ago
SELLAS Life Sciences Group Announces $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
MT Newswires
a month ago
SELLAS Life Sciences Shares Fall; Interim Trial Results on Acute Myeloid Leukemia Treatment Issued
GlobeNewswire
a month ago
SELLAS Life Sciences Announces Positive Outcome of Interim Analysis for its Pivotal Phase 3 REGAL Trial of GPS in Acute Myeloid Leukemia
GlobeNewswire
a month ago
SELLAS Announces Key Business Objectives for 2025
GlobeNewswire
2 months ago
SELLAS to Host Corporate Update Call on January 8, 2025, at 9:00 am ET
GlobeNewswire
2 months ago
SELLAS Life Sciences Triggers Interim Analysis in Phase 3 REGAL Trial of GPS in Acute Myeloid Leukemia
Compare SLS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SLS SELLAS Life Sciences Group Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.